Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trialMartina Schneider, Nina Wressnigg, Sebastian Toepfer et al.|The Lancet|2023Cited by 218
A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adultsRobert P. McMahon, Juan Carlos Jaramillo, Ulrike Fuchs et al.|Journal of Travel Medicine|2023Cited by 35